Illumina, Inc. vs Main Street Capital Corporation — how do they compare? Illumina, Inc. trades at $268.9 (market cap $39.95B), while Main Street Capital Corporation trades at $54.42 (market cap $5.09B). The key difference: Illumina, Inc. is far larger — about 7.8× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.84% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Main Street Capital Corporation for 88 Days on average.
| ILMN | MAIN | |
|---|---|---|
Market Cap | $39.95B | $5.09B |
Volume | 3,169,503 | 524,060 |
Sector | Health | Financials |
52-Week High | $293.69 | $64.60 |
52-Week Low | $91.00 | $49.63 |
Typical Hold Time | 83 Days | 88 Days |
Enterprise Value | $41.31B | $7.54B |
Dividend Yield | — | 5.84% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
MAIN trades at $54.18, down 1.08% on the day, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $592 million and net income of $493 million for 2025, with a net income margin of 83.36%. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1 2026. Analyst consensus is a Hold with a $58.33 price target, indicating modest upside potential.
Outlook: MAIN offers a stable dividend history and strong profitability, but faces headwinds from softening revenue projections for 2026 and negative operating cash flow. Risks include earnings volatility and high valuation multiples. The stock presents a cautious opportunity for income-focused investors, balanced by near-term fundamental pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →